As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations,  pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized. And while...

Behind the mAbs and repurposed antivirals in development for COVID-19 are at least 44 early stage small molecule, protein and oligonucleotide therapies that could find utility should SARS-CoV-2 become endemic or another coronavirus make the jump...

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting the lysosomal cysteine protease CTSC could suppress breast cancer lung metastases by blocking neutrophil extracellular trap (NET) formation. In patients, high breast tumor levels of CTSC protein were associated with...

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million on Dec. 7 in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed...

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed investors. Lumicell said...